BC Innovations | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BC Extra | Jul 25, 2019
Clinical News

July 25 Clinical Quick Takes: J&J’s ponesimod hits MS endpoint; plus a CRISPR first, Genkyotex and Aeglea

Janssen’s ponesimod tops Aubagio in Phase III  The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ) said it plans to submit NDAs to FDA and EMA this year after reporting ponesimod met the primary endpoint...
BC Innovations | Dec 19, 2018
Distillery Therapeutics

Cancer

INDICATION: Neuroendocrine tumors Cell culture and mouse studies suggest inhibiting arginine-mediated signaling of the ARG2-SLC7A1 axis could help treat neuroblastoma. In a human neuroblastoma cell line, an shRNA against ARG2 decreased proliferation compared with a...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BC Innovations | Nov 13, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest PEGylated ARG1 and dichloroacetate could help treat breast cancer. In a human triple-negative breast cancer (TNBC) and a human estrogen receptor-positive breast cancer cell line, the...
BioCentury | Jun 16, 2017
Product Development

Everywhere IDO

Incyte Corp. and partner Merck & Co. Inc. now have reported the data that led them to plan Phase III trials that combine their molecules in five cancer indications. For Incyte, the next step is...
BC Week In Review | May 19, 2017
Clinical News

Aeglea reports Phase I data for AEB1102

In March, Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) reported top-line data from a Phase I trial to treat arginase 1 (ARG1) deficiency showing that IV AEB1102 was well tolerated and reduced blood arginine levels to normal levels....
BioCentury | Apr 7, 2017
Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
BC Week In Review | Mar 30, 2017
Company News

Calithera, Incyte deal

Calithera will receive a $12 million milestone payment from Incyte under a January deal granting Incyte exclusive, worldwide rights to CB-1158 for hematology and cancer indications. Calithera said the milestone, the first under the deal,...
BC Week In Review | Feb 3, 2017
Company News

Calithera, Incyte deal

Calithera granted Incyte exclusive, worldwide rights to CB-1158 for hematology and cancer indications. The arginase 1 (ARG1) and ARG2 inhibitor is in a Phase I/II trial to treat advanced or metastatic solid tumors, with data...
Items per page:
1 - 10 of 25